The anti-tumor effect and increased tregs infiltration mediated by rAAV-SLC vector

[1]  R. Strieter,et al.  Intrapulmonary administration of CCL21 gene-modified dendritic cells reduces tumor burden in spontaneous murine bronchoalveolar cell carcinoma. , 2006, Cancer research.

[2]  寒川 延子.  CCR7 is critically important for migration of dendritic cells in intestinal lamina propria to mesenteric lymph nodes , 2006 .

[3]  T. Yamano,et al.  Enhancement of immunity by a DNA melanoma vaccine against TRP2 with CCL21 as an adjuvant. , 2006, Molecular therapy : the journal of the American Society of Gene Therapy.

[4]  Xiao Xiao,et al.  Long-term modifications of blood pressure in normotensive and spontaneously hypertensive rats by gene delivery of rAAV-mediated cytochrome P450 arachidonic acid hydroxylase , 2005, Cell Research.

[5]  Y. Kan,et al.  Adeno-Associated Viral Vector Delivered Cardiac-Specific and Hypoxia-Inducible VEGF Expression in the Ischemic Mouse Hearts , 2022 .

[6]  H. Kaufman,et al.  The lymphoid chemokine CCL21 costimulates naive T cell expansion and Th1 polarization of non-regulatory CD4+ T cells. , 2004, Cellular immunology.

[7]  A. O’Garra,et al.  Regulatory T cells and mechanisms of immune system control , 2004, Nature Medicine.

[8]  C. Piccirillo,et al.  Cornerstone of peripheral tolerance: naturally occurring CD4+CD25+ regulatory T cells. , 2004, Trends in immunology.

[9]  M. Huang,et al.  Intratumoral Administration of Dendritic Cells Overexpressing CCL21 Generates Systemic Antitumor Responses and Confers Tumor Immunity , 2004, Clinical Cancer Research.

[10]  Y. Koyanagi,et al.  Synergistic antitumor effect by coexpression of chemokine CCL21/SLC and costimulatory molecule LIGHT , 2004, Cancer Gene Therapy.

[11]  M. Moser,et al.  CD4+ CD25+ Regulatory T Cells Control T Helper Cell Type 1 Responses to Foreign Antigens Induced by Mature Dendritic Cells In Vivo , 2003, The Journal of experimental medicine.

[12]  S. Fan,et al.  Long‐term expression of angiostatin suppresses metastatic liver cancer in mice , 2003, Hepatology.

[13]  M. Huang,et al.  SLC/CCL21-mediated anti-tumor responses require IFNγ, MIG/CXCL9 and IP-10/CXCL10 , 2003, Molecular Cancer.

[14]  F. Ramsdell,et al.  An essential role for Scurfin in CD4+CD25+ T regulatory cells , 2003, Nature Immunology.

[15]  T. Nomura,et al.  Control of Regulatory T Cell Development by the Transcription Factor Foxp3 , 2002 .

[16]  C. Martínez-A,et al.  CCR7-mediated physiological lymphocyte homing involves activation of a tyrosine kinase pathway. , 2003, Blood.

[17]  H. Federoff,et al.  Herpes simplex virus (HSV) amplicon-mediated codelivery of secondary lymphoid tissue chemokine and CD40L results in augmented antitumor activity. , 2002, Cancer research.

[18]  C. Cohen,et al.  Roles of SLC/CCL21 and CCR7 in Human Kidney for Mesangial Proliferation, Migration, Apoptosis, and Tissue Homeostasis1 , 2002, The Journal of Immunology.

[19]  T. Wagner,et al.  Combined HSV-TK/GCV and secondary lymphoid tissue chemokine gene therapy inhibits tumor growth and elicits potent antitumor CTL response in tumor-bearing mice. , 2002, Anticancer research.

[20]  Osamu Yoshie,et al.  Role for CCR7 ligands in the emigration of newly generated T lymphocytes from the neonatal thymus. , 2002, Immunity.

[21]  M. Carson,et al.  A Ligand for the Chemokine Receptor CCR7 Can Influence the Homeostatic Proliferation of CD4 T Cells and Progression of Autoimmunity1 , 2001, The Journal of Immunology.

[22]  R. Strieter,et al.  Secondary lymphoid organ chemokine reduces pulmonary tumor burden in spontaneous murine bronchoalveolar cell carcinoma. , 2001, Cancer research.

[23]  Rolf M. Zinkernagel,et al.  Roles of tumour localization, second signals and cross priming in cytotoxic T-cell induction , 2001, Nature.

[24]  E. Shevach.  Certified Professionals , 2001, The Journal of experimental medicine.

[25]  J. Mulé,et al.  T cell-dependent antitumor immunity mediated by secondary lymphoid tissue chemokine: augmentation of dendritic cell-based immunotherapy. , 2001, Cancer research.

[26]  S. Fujita,et al.  Enhancement of anti‐tumor immunity by tumor cells transfected with the secondary lymphoid tissue chemokine EBI‐1‐ligand chemokine and stromal cell–derived factor‐1αchemokine genes , 2001, International journal of cancer.

[27]  T. Kakiuchi,et al.  Mice Lacking Expression of the Chemokines Ccl21-Ser and Ccl19 (plt Mice) Demonstrate Delayed but Enhanced T Cell Immune Responses , 2001, The Journal of experimental medicine.

[28]  Hyun Chul Lee,et al.  Remission in models of type 1 diabetes by gene therapy using a single-chain insulin analogue , 2000, Nature.

[29]  C. Caux,et al.  Antitumor Effects of the Mouse Chemokine 6Ckine/SLC Through Angiostatic and Immunological Mechanisms1 , 2000, The Journal of Immunology.

[30]  R. Schreiber,et al.  Eradication of established tumors by CD8+ T cell adoptive immunotherapy. , 2000, Immunity.

[31]  M. Burdick,et al.  Secondary Lymphoid Tissue Chemokine Mediates T Cell-Dependent Antitumor Responses In Vivo1 , 2000, The Journal of Immunology.

[32]  E. Wolf,et al.  CCR7 Coordinates the Primary Immune Response by Establishing Functional Microenvironments in Secondary Lymphoid Organs , 1999, Cell.

[33]  P. Lollini,et al.  Specific and nonspecific immunity in the prevention of spontaneous tumours. , 1999, Immunology today.

[34]  L. Williams,et al.  Secondary lymphoid-tissue chemokine (SLC) is chemotactic for mature dendritic cells. , 1999, Blood.

[35]  H. Broxmeyer,et al.  CCR7 ligands, SLC/6Ckine/Exodus2/TCA4 and CKbeta-11/MIP-3beta/ELC, are chemoattractants for CD56(+)CD16(-) NK cells and late stage lymphoid progenitors. , 1999, Cellular immunology.

[36]  S. Hudak,et al.  The CC Chemokine Receptor-7 Ligands 6Ckine and Macrophage Inflammatory Protein-3β Are Potent Chemoattractants for In Vitro- and In Vivo-Derived Dendritic Cells , 1999, The Journal of Immunology.

[37]  P. Klenerman,et al.  Immune surveillance against a solid tumor fails because of immunological ignorance. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[38]  L. Williams,et al.  Mice Lacking Expression of Secondary Lymphoid Organ Chemokine Have Defects in Lymphocyte Homing and Dendritic Cell Localization , 1999, The Journal of experimental medicine.

[39]  D. Erle,et al.  Secondary Lymphoid-Tissue Chemokine (SLC) Stimulates Integrin α4β7-Mediated Adhesion of Lymphocytes to Mucosal Addressin Cell Adhesion Molecule-1 (MAdCAM-1) Under Flow , 1998, The Journal of Immunology.

[40]  N. Copeland,et al.  The CC chemokine 6Ckine binds the CXC chemokine receptor CXCR3. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[41]  M. Baggiolini,et al.  The chemokine SLC is expressed in T cell areas of lymph nodes and mucosal lymphoid tissues and attracts activated T cells via CCR7 , 1998, European journal of immunology.

[42]  E. Butcher,et al.  6-C-kine (SLC), a Lymphocyte Adhesion-triggering Chemokine Expressed by High Endothelium, Is an Agonist for the MIP-3β Receptor CCR7 , 1998, The Journal of cell biology.

[43]  H. Nomiyama,et al.  A lymphocyte‐specific CC chemokine, secondary lymphoid tissue chemokine (SLC), is a highly efficient chemoattractant for B cells and activated T cells , 1998, European journal of immunology.

[44]  O. Yoshie,et al.  Secondary Lymphoid-tissue Chemokine Is a Functional Ligand for the CC Chemokine Receptor CCR7* , 1998, The Journal of Biological Chemistry.

[45]  J. Cyster,et al.  A chemokine expressed in lymphoid high endothelial venules promotes the adhesion and chemotaxis of naive T lymphocytes. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[46]  D. Erle,et al.  Secondary lymphoid-tissue chemokine (SLC) stimulates integrin alpha 4 beta 7-mediated adhesion of lymphocytes to mucosal addressin cell adhesion molecule-1 (MAdCAM-1) under flow. , 1998, Journal of immunology.

[47]  Andrew Freese,et al.  In vivo expression of therapeutic human genes for dopamine production in the caudates of MPTP-treated monkeys using an AAV vector , 1998, Gene Therapy.

[48]  M. Klemsz,et al.  Isolation and characterization of Exodus-2, a novel C-C chemokine with a unique 37-amino acid carboxyl-terminal extension. , 1997, Journal of immunology.

[49]  M. Ridanpää,et al.  Molecular Cloning of a Novel Human CC Chemokine Secondary Lymphoid-Tissue Chemokine That Is a Potent Chemoattractant for Lymphocytes and Mapped to Chromosome 9p13* , 1997, The Journal of Biological Chemistry.

[50]  J. Bluestone,et al.  Antigenic Cancer Cells Grow Progressively in Immune Hosts without Evidence for T Cell Exhaustion or Systemic Anergy , 1997, The Journal of experimental medicine.

[51]  B. Byrne,et al.  Gene delivery to skeletal muscle results in sustained expression and systemic delivery of a therapeutic protein. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[52]  S. Burdach,et al.  Combined chemokine and cytokine gene transfer enhances antitumor immunity , 1996, Nature Medicine.

[53]  D. Goeddel,et al.  RANTES secretion by gene-modified tumor cells results in loss of tumorigenicity in vivo: role of immune cell subpopulations. , 1996, Human gene therapy.

[54]  M. Toda,et al.  Immunologic self-tolerance maintained by activated T cells expressing IL-2 receptor alpha-chains (CD25). Breakdown of a single mechanism of self-tolerance causes various autoimmune diseases. , 1995, Journal of immunology.

[55]  Donald W. Pfaff,et al.  Long-term gene expression and phenotypic correction using adeno-associated virus vectors in the mammalian brain , 1994, Nature Genetics.